



2740  
AF 2

PATENT  
Customer No. 22,852  
Attorney Docket No. 03495.0217-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Schwartz et al. ) Group Art Unit: 1648  
)  
Application No.: 10/083,678 ) Examiner: PARKIN, J.  
)  
Filed: February 27, 2002 ) Confirmation No. 9442  
)  
For: MHC-I-RESTRICTED PRESENTATION OF HIV-1 VIRION ANTIGENS  
WITHOUT VIRAL REPLICATION. APPLICATION TO THE STIMULATION OF  
CTL AND VACCINATION *IN VIVO*; ANALYSIS OF VACCINATING  
COMPOSITION *IN VITRO*

**Mail Stop AF**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**TRANSMITTAL LETTER**

Applicants enclose the following papers:

1. Information Disclosure Statement under 37 C.F.R. § 1.97(d) (2 pages);
2. PTO Form SB/08 (1 page) and one document; and
3. \$180 Check for requisite Information Disclosure Fees.


Kindly associate this submission with the above-identified application.


Please grant any extensions of time required to enter these papers and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: May 19, 2005

By:   
Salvatore J. Arrigo  
Reg. No. 46,063  
Tel.: (202) 408-4160  
Fax.: (202) 408-4400  
E-mail: [arrigos@finnegan.com](mailto:arrigos@finnegan.com)



PATENT  
Customer No. 22,852  
Attorney Docket No. 03495.0217-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Schwartz et al. ) Group Art Unit: 1648  
)  
Application No.: 10/083,678 ) Examiner: PARKIN, J.  
)  
Filed: February 27, 2002 ) Confirmation No. 9442  
)  
For: MHC-I-RESTRICTED PRESENTATION OF HIV-1 VIRION ANTIGENS  
WITHOUT VIRAL REPLICATION. APPLICATION TO THE STIMULATION OF  
CTL AND VACCINATION *IN VIVO*; ANALYSIS OF VACCINATING  
COMPOSITION *IN VITRO*

**Mail Stop AF**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(d)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), applicants bring to the attention of the Examiner the document on the attached listing. This Information Disclosure Statement is being filed after a Final Action but before payment of the Issue Fee and is accompanied by a fee of \$180.00 as specified under § 1.17(p) and a certification as specified under § 1.97(e). Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making appropriate notations on the attached form.

The document listed in this Information Disclosure Statement was first cited in a communication from the European Patent Office in a counterpart foreign application, and this Information Disclosure Statement is being filed within three months of the mailing date of that communication.

A copy of the listed foreign and non-patent literature document is attached.

Copies of U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is material or constitute "prior art." If the Examiner applies the document as prior art against any claims in the application and applicants determine that the cited document does not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should it be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: May 19, 2005

By: 

Salvatore J. Arrigo, Reg. No. 46,063  
Tel.: (202) 408-4160 Fax.: (202) 408-4400  
E-mail: arrigos@finnegan.com



PDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/083,678
				Filing Date	February 27, 2002
				First Named Inventor	SCHWARTZ et al.
				Art Unit	1648
				Examiner Name	J. PARKIN
Sheet	1	of	1	Attorney Docket Number	03495.0217-00

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		HAGLUND et al., "Expression of Human Immunodeficiency Virus Type 1 Gag Protein Precursor and Envelope Proteins from a Vesicular Stomatitis Virus Recombinant: High-Level Production of Virus-like Particles Containing HIV Envelope," Virology Vol. 268:112-121 (2000)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.